Updated Covid Vaccines Not Urgently Needed With Mild Surge: Former CSIR-IGIB Chief To News18
There's no need to panic, said Anurag Agrawal, as Covid-19, in its current form, is expected to stay mild for the majority
Updated Covid vaccines may not be necessary at this stage, especially in a country like India, where the younger population is less vulnerable to severe outcomes, Anurag Agrawal, former director of the Institute of Genomics and Integrative Biology (IGIB), told News18.
IGIB is a national laboratory of the Council of Scientific & Industrial Research (CSIR).
India is witnessing a Covid-19 surge, with a total of 1,010 active cases as of May 26, 2025. The highest number of active cases is in Kerala (430), followed by Maharashtra (210), Delhi (104), and Gujarat (83).
'The current rise in cases can be attributed to waning antibody levels and minor mutations in the virus's spike protein," said Agrawal.
Globally, Agrawal believes the newly updated Covid-19 vaccines are not proving highly effective against emerging strains. 'While mRNA technology allows for rapid updates to match circulating variants, it remains the only platform capable of such flexibility. Other vaccine technologies take much longer to develop and distribute; by the time they are ready, the infection wave often begins to fade," said Agrawal, who is presently dean of the Trivedi School of Biosciences at Ashoka University.
advetisement
Even with mRNA, he said, there is ongoing debate about its use, hinting towards concerns ranging from long-term safety data to accessibility.
'India is currently seeing cases of the JN.1 strain. However, with a relatively younger demographic and a lower risk of severe disease, there is doubt among experts whether updating vaccines for this specific strain is worthwhile," he said.
According to Agrawal, who is also head of the Koita Centre for Digital Health at Ashoka University, many people may be silent carriers of the virus, showing no symptoms. Additionally, actual case numbers could be much higher than reported, as fewer people are opting for Covid-19 testing.
Despite this, he maintains that no drastic measures are required beyond surveillance and preparedness.
'The susceptibility to severe illness remains low. For those who are highly vulnerable, such as the elderly or immunocompromised, simple precautions remain the best line of defence," said Agrawal, who is a well-known physician-scientist. 'In short, the message is clear: there's no need to panic. Covid-19, in its current form, is expected to stay mild for the majority. A calm, precautionary approach is all that is needed."
About the Author
Himani Chandna
First Published:
May 31, 2025, 07:00 IST
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
Why India's hepatitis crisis needs urgent attention
World Hepatitis Day, observed on July 28, is a global call to action to eliminate viral hepatitis, the second deadliest infectious disease after COVID-19. This year's theme, 'Hepatitis: Let's Break It Down', urges the dismantling of financial, social, and systemic barriers that delay timely diagnosis, treatment, and prevention of this silent killer. Understanding hepatitis Hepatitis refers to inflammation of the liver, primarily caused by five viruses: A, B, C, D, and E. Hepatitis A and E are transmitted through contaminated food or water and usually result in acute illness. Hepatitis B, C, and D, however, are more insidious and are transmitted through blood, unsafe medical procedures, unprotected sex, or from mother to child. If left untreated, these can lead to chronic liver disease, cirrhosis, or liver cancer. According to the World Health Organization's 2024 Global Hepatitis Report, India bears the world's second-highest burden, with 2.98 crore Hepatitis B and 55 lakh Hepatitis C cases. Alarmingly, nearly 90% of those infected are unaware of their condition and often present only when irreversible liver damage has set in. Despite the availability of vaccines for Hepatitis A and B, and curative treatments for Hepatitis C, hepatitis still claims one life every 30 seconds. Challenges that need addressing In line with the WHO's target to eliminate viral hepatitis as a public health threat by 2030, India must address pressing challenges such as high diagnostic costs, limited screening, and persistent stigma. Strengthening the healthcare response through routine screening, community-level education, and policies that ensure affordable access to diagnostics and treatment is essential. Across the country, public health institutions, medical colleges, and civil society partners are intensifying efforts through awareness campaigns, screening programs, and policy advocacy to improve access to diagnosis and treatment. Recent initiatives have included national summits bringing together experts and stakeholders to develop comprehensive elimination strategies. On this World Hepatitis Day, let's break the silence, end the stigma, and build a hepatitis-free world. Join the movement. Get tested, get treated, and protect your family. (Dr. Vivek Shanmugam is a liver transplant surgeon & managing trustee, Chennai Liver Foundation . Info@
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Long-Covid, viruses: New research looks for links to chronic fatigue
Millions of people who recover from infections like Covid-19, influenza and glandular fever are affected by long-lasting symptoms. These include chronic fatigue, brain fog, exercise intolerance, dizziness, muscle or joint pain and gut problems. And many of these symptoms worsen after exercise, a phenomenon known as post-exertional malaise. Medically the symptoms are known as myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). The World Health Organization classifies this as a post viral fatigue syndrome, and it is recognised by both the WHO and the United States Centers for Disease Control and Prevention as a brain disorder. Experiencing illness long after contracting an infection is not new, as patients have reported these symptoms for decades. But Covid-19 has amplified the problem worldwide. Nearly half of people with ongoing post-Covid symptoms – a condition known as long-Covid– now meet the criteria for ME/CFS. Since the start of the pandemic in 2020, it is estimated that more than 400 million people have developed long-Covid. To date, no widely accepted and testable mechanism has fully explained the biological processes underlying long-Covid and ME/CFS. Our work offers a new perspective that may help close this gap. Our research group studies blood and the cardiovascular system in inflammatory diseases, as well as post-viral conditions. We focus on coagulation, inflammation and endothelial cells. Endothelial cells make up the inner layer of blood vessels and serve many important functions, like regulating blood clotting, blood vessel dilation and constriction, and inflammation. Our latest review aims to explain how ME/CFS and long-Covid start and progress, and how symptoms show up in the body and its systems. By pinpointing and explaining the underlying disease mechanisms, we can pave the way for better clinical tools to diagnose and treat people living with ME/CFS and long-Covid. What is endothelial senescence? In our review, our international team proposes that certain viruses drive endothelial cells into a half-alive, 'zombie-like' state called cellular senescence. Senescent endothelial cells stop dividing, but continue to release molecules that awaken and confuse the immune system. This prompts the blood to form clots and, at the same time, prevent clot breakdown, which could lead to the constriction of blood vessels and limited blood flow. By placing 'zombie' blood-vessel cells at the centre of these post-viral diseases, our hypothesis weaves together microclots, oxygen debt (the extra oxygen your body needs after strenuous exercise to restore balance), brain-fog, dizziness, gut leakiness (a digestive condition where the intestinal lining allows toxins into the bloodstream) and immune dysfunction into a single, testable narrative. From acute viral infection to 'zombie' vessels Viruses like SARS-CoV-2, Epstein–Barr virus, HHV-6, influenza A, and enteroviruses (a group of viruses that cause a number of infectious illnesses which are usually mild) can all infect endothelial cells. They enable a direct attack on the cells that line the inside of blood vessels. Some of these viruses have been shown to trigger endothelial senescence. Multiple studies show that SARS-CoV-2 (the virus which causes Covid-19 disease) has the ability to induce senescence in a variety of cell types, including endothelial cells. Viral proteins from SARS-CoV-2, for example, sabotage DNA-repair pathways and push the host cell towards a senescent state, while senescent cells in turn become even more susceptible to viral entry. This reciprocity helps explain why different pathogens can result in the same chronic illness. Influenza A, too, has shown the ability to drive endothelial cells into a senescent, zombie-like state. What we think is happening We propose that when blood-vessel cells turn into 'zombies', they pump out substances that make blood thicker and prone to forming tiny clots. These clots slow down circulation, so less oxygen reaches muscles and organs. This is one reason people feel drained. During exercise, the problem worsens. Instead of the vessels relaxing to allow adequate bloodflow, they tighten further. This means that muscles are starved of oxygen and patients experience a crash the day after exercise. In the brain, the same faulty cells let blood flow drop and leak, bringing on brain fog and dizziness. In the gut, they weaken the lining, allowing bits of bacteria to slip into the bloodstream and trigger more inflammation. Because blood vessels reach every corner of the body, even scattered patches of these 'zombie' cells found in the blood vessels can create the mix of symptoms seen in long-Covid and ME/CFS. Immune exhaustion locks in the damage Some parts of the immune system kill senescent cells. They are natural-killer cells, macrophages and complement proteins, which are immune molecules capable of tagging and killing pathogens. But long-Covid and ME/CFS frequently have impaired natural-killer cell function, sluggish macrophages and complement dysfunction. Senescent endothelial cells may also send out a chemical signal to repel immune attack. So the 'zombie cells' actively evade the immune system. This creates a self-sustaining loop of vascular and immune dysfunction, where senescent endothelial cells persist. In a healthy person with an optimally functioning immune system, these senescent endothelial cells will normally be cleared. But there is significant immune dysfunction in ME/CFS and long-Covid, and this may enable the 'zombie cells' to survive and the disease to progress. Where the research goes next There is a registered clinical trial in the US that is investigating senescence in long-Covid. Our consortium is testing new ways to spot signs of ageing in the cells that line our blood vessels. First, we expose healthy endothelial cells in the lab to blood from patients to see whether it pushes the cells into a senescent, or 'zombie,' state. At the same time, we are trialling non-invasive imaging and fluorescent probes that could one day reveal these ageing cells inside the body. In selected cases, tissue biopsies may later confirm what the scans show. Together, these approaches aim to pinpoint how substances circulating in the blood drive cellular ageing and how that, in turn, fuels disease. Our aim is simple: find these ageing endothelial cells in real patients. Pinpointing them will inform the next round of clinical trials and open the door to therapies that target senescent cells directly, offering a route to healthier blood vessels and, ultimately, lighter disease loads.
Time of India
12 hours ago
- Time of India
US lawmakers press FDA to target knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market-a problem that emerged over the last year. Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity MCA Data Science Degree Leadership PGDM Public Policy Operations Management others Others Product Management healthcare Digital Marketing MBA Technology Project Management CXO Finance Artificial Intelligence Healthcare Data Analytics Management Design Thinking Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details "We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications," they wrote in a letter to FDA commissioner Marty Makary. "Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo The group-spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey-asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the "urgency" of the situation. Live Events A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a "complete and thorough" response to the issues raised in the lawmakers' letter. "Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously," the spokesperson said. "And we are deeply committed to strengthening the oversight of imported products at US ports of entry." In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. "We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs," said a spokesperson for Hims & Hers Health, one of the telehealth firms that sells compounded GLP-1s. "We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first." Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
